Sirio Pharma Co., Ltd.

Shenzhen Stock Exchange 300791.SZ

Sirio Pharma Co., Ltd. Return on Assets (ROA) for the year ending December 31, 2023: 5.41%

Sirio Pharma Co., Ltd. Return on Assets (ROA) is 5.41% for the year ending December 31, 2023, a 6.65% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Sirio Pharma Co., Ltd. Return on Assets (ROA) for the year ending December 31, 2022 was 5.07%, a -16.43% change year over year.
Sirio Pharma Co., Ltd. Return on Assets (ROA) for the year ending December 31, 2021 was 6.07%, a -37.52% change year over year.
Sirio Pharma Co., Ltd. Return on Assets (ROA) for the year ending December 31, 2020 was 9.71%, a 60.77% change year over year.
Sirio Pharma Co., Ltd. Return on Assets (ROA) for the year ending December 31, 2019 was 6.04%, a -54.11% change year over year.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

Shenzhen Stock Exchange: 300791.SZ

Sirio Pharma Co., Ltd.

CEO	Mr. Peiqing Li
IPO Date	Sept. 25, 2019
Location	China
Headquarters	No.83 Taishan Road
Employees	2,610
Sector	Consumers Staples
Industries Non-Alcoholic Beverages Consumer Packaged Goods Cosmetics Personal Care Pet Food Pharmaceuticals Plastics Soft Drinks & Sodas

Description

Sirio Pharma Co., Ltd. operates as a contract manufacturer for dietary supplements to customers worldwide. The company develops and manufactures a range of softgel dietary supplements; vegetarian softgel; various nutraceutical gummies; probiotic products; tablet and powder products; capsules; and functional beverages. It also offers a range of services, including primary and final packaging. Sirio Pharma Co., Ltd. was founded in 1993 and is headquartered in Shantou, China.

Key trends

Past 5 years